Paraneoplastic syndromes

Lambert-Eaton Myasthenic Syndrome (LEMS) Market and Pipeline Insight, 2020 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020

The "Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Lambert-Eaton Myasthenic Syndrome (LEMS)- Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Lambert-Eaton Myasthenic Syndrome (LEMS) market.
  • A detailed picture of the Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline landscape is provided, which includes the disease overview and Lambert-Eaton Myasthenic Syndrome (LEMS) treatment guidelines.
  • The assessment part of the report embraces in-depth Lambert-Eaton Myasthenic Syndrome (LEMS) commercial assessment and clinical assessment of the Lambert-Eaton Myasthenic Syndrome (LEMS) pipeline products from the pre-clinical developmental phase to the marketed phase.

Carcinoid Syndrome | 2020 Pipeline Landscape Overview and Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, April 20, 2020

Carcinoid Syndrome Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Carcinoid Syndrome market.

Key Points: 
  • Carcinoid Syndrome Pipeline Insight, 2020 outlays comprehensive insights of present clinical development scenario and growth prospects across the Carcinoid Syndrome market.
  • A detailed picture of the Carcinoid Syndrome pipeline landscape is provided, which includes the disease overview and Carcinoid Syndrome treatment guidelines.
  • The assessment part of the report embraces in-depth Carcinoid Syndrome commercial assessment and clinical assessment of the Carcinoid Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase.
  • How many Carcinoid Syndrome emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Carcinoid Syndrome?

New HealthWell Foundation Fund Offers Financial Assistance to People Living with Lambert-Eaton Myasthenic Syndrome (LEMS)

Retrieved on: 
Friday, December 27, 2019

GERMANTOWN, Md., Dec. 27, 2019 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to people living with Lambert-Eaton Myasthenic Syndrome (LEMS).

Key Points: 
  • GERMANTOWN, Md., Dec. 27, 2019 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has opened a new fund to provide copayment and premium assistance to people living with Lambert-Eaton Myasthenic Syndrome (LEMS).
  • Under the new fund, HealthWell will provide up to $12,000 in financial assistance for a 12-month grant to eligible patients who have annual household incomes up to 500 percent of the federal poverty level.
  • HealthWell Foundation's new fund provides financial assistance for these patients so they can focus on managing their condition."
  • To determine eligibility and apply for financial assistance, visit HealthWell's Lambert-Eaton Myasthenic Syndrome (LEMS) Fund page.

Global Lambert-Eaton Myasthenic Syndrome (LEMS) Market Insights, Epidemiology, and Market Forecast to 2028

Retrieved on: 
Monday, September 16, 2019

DUBLIN, Sept. 16, 2019 /PRNewswire/ -- The "Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 16, 2019 /PRNewswire/ -- The "Lambert-Eaton Myasthenic Syndrome (LEMS) - Market Insights, Epidemiology, and Market Forecast to 2028" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Lambert-Eaton Myasthenic Syndrome (LEMS) from 2017 to 2028 segmented by seven major markets.
  • The Lambert-Eaton Myasthenic Syndrome (LEMS) market report gives a thorough understanding of the Lambert-Eaton Myasthenic Syndrome (LEMS) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.
  • It also provides treatment algorithms and treatment guidelines for Lambert-Eaton Myasthenic Syndrome (LEMS) in the US, Europe, and Japan.